{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:16:58Z","timestamp":1790835418283,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MGC Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dementia is a neurological condition that affects the cognitive and functional ability of the brain and is the leading cause of disability among those aged 65 years and above. More effective ways to manage dementia symptoms are needed because current treatment options (antidepressants and antipsychotics) can be ineffective and are associated with substantial side effects, including increased rate of mortality. Cannabinoid-based medicine (CBM) has shown an ability to inhibit some symptoms associated with dementia, and the adverse effects are often minimal; yet, little research has explored the use of CBM among this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To monitor the safety of a purified dose of CBM oil (3:2 delta-9-tetrahydrocannabinol:cannabidiol) on behaviour symptoms, quality of life and discomfort caused by pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/design<\/jats:title>\n                    <jats:p>We will carry out an 18-week, randomised, double-blind crossover trial that consists of a 2-week eligibility period, two 6-week treatment cycles, and two 2-week washout periods (between both cycles and after the second treatment cycle). We aim to recruit 50 participants with dementia who are living in residential aged-care facilities. The participants will be randomised into two groups and will receive a dose of either CBM oil or placebo for the first treatment cycle and the opposite medication for the second. Data will be collected using the Neuropsychiatric Inventory Questionnaire, the Cohen-Mansfield Agitation Inventory, the Quality of Life in Alzheimer\u2019s Disease questionnaire, and the Abbey Pain Scale on seven occasions. These will be completed by the participants, aged-care staff, and nominated next of kin or family members. The participants\u2019 heart rate and blood pressure will be monitored weekly, and their body composition and weight will be monitored fortnightly by a research nurse, to assess individual dose response and frailty. In addition, pre- and post-surveys will be administered to aged-care staff and family members to understand their perceptions of CBM and to inform proposed focus groups consisting of the aged-care staff and next of kin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The study design has been informed by medical professionals and key stakeholders, including those working in the residential aged-care industry to ensure patient safety, collection of non-invasive measures, and methodological rigor and study feasibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Australian New Zealand Clinical Trials Registry,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=375128&amp;isClinicalTrial=False\">ACTRN12619000474156<\/jats:ext-link>\n                      . Registered on 21 March 2019\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-020-4085-x","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T10:04:54Z","timestamp":1581674694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Use of cannabinoid-based medicine among older residential care recipients diagnosed with dementia: study protocol for a double-blind randomised crossover trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-5937","authenticated-orcid":false,"given":"Amanda","family":"Timler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bulsara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Bulsara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Vickery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Codde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"4085_CR1","unstructured":"Alzheimer\u2019s Disease International. The global voice on dementia 2017. https:\/\/www.alz.co.uk\/. Accessed 5 Jan 2018."},{"issue":"6","key":"4085_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1017\/S1092852917000530","volume":"23","author":"A Anand","year":"2018","unstructured":"Anand A, Khurana P, Chawla J, Sharma N, Khurana N. Emerging treatments for the behavioral and psychological symptoms of dementia. CNS Spectr. 2018;23(6):361\u20139.","journal-title":"CNS Spectr"},{"issue":"4","key":"4085_CR3","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jgs.12730","volume":"62","author":"HC Kales","year":"2014","unstructured":"Kales HC, Gitlin LN, Lyketsos CG. Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"4085_CR4","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1002\/gps.4788","volume":"33","author":"M Sun","year":"2018","unstructured":"Sun M, Mainland BJ, Ornstein TJ, Mallya S, Fiocco AJ, Sin GL, et al. The association between cognitive fluctuations and activities of daily living and quality of life among institutionalized patients with dementia. Int J Geriatr Psychiatry. 2018;33(2):e280\u20135.","journal-title":"Int J Geriatr Psychiatry"},{"key":"4085_CR5","volume-title":"Dementia","author":"Australian Institute of Health and Welfare","year":"2016","unstructured":"Australian Institute of Health and Welfare. Dementia. 2016. https:\/\/www.aihw.gov.au\/reports-data\/health-conditions-disability-deaths\/dementia\/overview. Accessed 22 Feb 2018."},{"issue":"11","key":"4085_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jagp.2016.08.015","volume":"24","author":"IM Antonsdottir","year":"2016","unstructured":"Antonsdottir IM, Makino KM, Porsteinsson AP. Dazed and confused: medical cannabis in Alzheimer disease. Am J Geriatr Psychiatry. 2016;24(11):1004\u20136.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"4085_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/14656566.2017.1307340","volume":"18","author":"AP Porsteinsson","year":"2017","unstructured":"Porsteinsson AP, Antonsdottir IM. An update on the advancements in the treatment of agitation in Alzheimer\u2019s disease. Expert Opin Pharmacother. 2017;18(6):611\u201320.","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"4085_CR8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2011.1360","volume":"306","author":"AR Maher","year":"2011","unstructured":"Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359\u201369.","journal-title":"JAMA"},{"issue":"2","key":"4085_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jfma.2012.09.002","volume":"114","author":"YT Lin","year":"2015","unstructured":"Lin YT, Hwang TJ, Shan JC, Chiang HL, Sheu YH, Hwu HG. Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis. J Formos Med Assoc. 2015;114(2):147\u201353.","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"4085_CR10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1474-4422(05)70219-2","volume":"4","author":"I McKeith","year":"2005","unstructured":"McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005;4(11):735\u201342.","journal-title":"Lancet Neurol"},{"issue":"1","key":"4085_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12877-015-0127-8","volume":"15","author":"A Foebel","year":"2015","unstructured":"Foebel A, Ballokova A, Wellens NIH, Fialova D, Milisen K, Liperoti R, et al. A retrospective, longitudinal study of factors associated with new antipsychotic medication use among recently admitted long-term care residents. BMC Geriatr. 2015;15(1):128.","journal-title":"BMC Geriatr"},{"key":"4085_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jpsychires.2016.05.013","volume":"80","author":"M Fakhoury","year":"2016","unstructured":"Fakhoury M. Could cannabidiol be used as an alternative to antipsychotics? J Psychiatr Res. 2016;80:14\u201321.","journal-title":"J Psychiatr Res"},{"issue":"4","key":"4085_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jagp.2012.11.022","volume":"22","author":"MR Woodward","year":"2014","unstructured":"Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry. 2014;22(4):415\u20139.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"14","key":"4085_CR14","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1007\/s00213-015-3889-y","volume":"232","author":"AI Ahmed","year":"2015","unstructured":"Ahmed AI, van den Elsen GA, Colbers A, Kramers C, Burger DM, van der Marck MA, Olde Rikkert MGM. Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia. Psychopharmacology. 2015;232(14):2587\u201395.","journal-title":"Psychopharmacology"},{"issue":"8","key":"4085_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11910-017-0766-6","volume":"17","author":"M Weier","year":"2017","unstructured":"Weier M, Hall W. The use of cannabinoids in treating dementia. Curr Neurol Neurosci Rep. 2017;17(8):56.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"9","key":"4085_CR16","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","volume":"12","author":"L Volicer","year":"1997","unstructured":"Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 1997;12(9):913\u20139.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"8","key":"4085_CR17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.4088\/JCP.15r10036","volume":"77","author":"ST Wilkinson","year":"2016","unstructured":"Wilkinson ST, Radhakrishnan R, D\u2019Souza DC. A systematic review of the evidence for medical marijuana in psychiatric indications. J Clin Psychiatry. 2016;77(8):1050\u201364.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"4085_CR18","first-page":"76","volume":"19","author":"M Hausman-Kedem","year":"2017","unstructured":"Hausman-Kedem M, Kramer U. Efficacy of medical cannabis for treating refractory epilepsy in children and adolescents, with emphasis on the Israel experience. Isr Med Assoc J. 2017;19(2):76\u20138.","journal-title":"Isr Med Assoc J"},{"key":"4085_CR19","first-page":"CD007204","volume":"2","author":"S Krishnan","year":"2009","unstructured":"Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 2009;2:CD007204.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"4085_CR20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cpt.119","volume":"97","author":"B Le Foll","year":"2015","unstructured":"Le Foll B, Tyndale RF. Cannabinoids: friend or foe? Clin Pharmacol Ther. 2015;97(6):528\u201331.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"4085_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.mayocp.2011.10.003","volume":"87","author":"JM Bostwick","year":"2012","unstructured":"Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc. 2012;87(2):172\u201386.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"4085_CR22","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3233\/JAD-140093","volume":"42","author":"CH Cao","year":"2014","unstructured":"Cao CH, Li YQ, Liu H, Bai G, Mayl J, Lin XY, et al. The potential therapeutic effects of THC on Alzheimer\u2019s disease. J Alzheimers Dis. 2014;42(3):973\u201384.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"4085_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/JAD-150915","volume":"51","author":"A Shelef","year":"2016","unstructured":"Shelef A, Barak Y, Berger U, Paleacu D, Tadger S, Plopsky I, et al. Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study. J Alzheimers Dis. 2016;51(1):15\u20139.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"4085_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/15622975.2017.1285049","volume":"20","author":"JM Khoury","year":"2019","unstructured":"Khoury JM, de Castro Louren\u00e7o das Neves M, Valente Roque MA, et al. Is there a role for cannabidiol in psychiatry? World J Biol Psychiatry. 2019;20(2):101\u201316.","journal-title":"World J Biol Psychiatry"},{"issue":"11","key":"4085_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/da.22664","volume":"34","author":"J Turna","year":"2017","unstructured":"Turna J, Patterson B, Ameringen M. Is cannabis treatment for anxiety, mood, and related disorders ready for prime time? Depress Anxiety. 2017;34(11):1006\u201317.","journal-title":"Depress Anxiety"},{"key":"4085_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fphar.2014.00037","volume":"5","author":"E Aso","year":"2014","unstructured":"Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer\u2019s disease: moving toward the clinic. Front Pharmacol. 2014;5:37.","journal-title":"Front Pharmacol"},{"issue":"11","key":"4085_CR27","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1002\/pro.3275","volume":"26","author":"B Nizynski","year":"2017","unstructured":"Nizynski B, Dzwolak W, Nieznanski K. Amyloidogenesis of Tau protein. Protein Sci. 2017;26(11):2126\u201350.","journal-title":"Protein Sci"},{"issue":"2","key":"4085_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1017\/S1041610214001720","volume":"27","author":"M Soto","year":"2015","unstructured":"Soto M, Andrieu S, Nourhashemi F, Ousset PJ, Ballard C, Robert P, et al. Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. Int Psychogeriatr. 2015;27(2):181\u201397.","journal-title":"Int Psychogeriatr"},{"issue":"8","key":"4085_CR29","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.3390\/ph3082689","volume":"3","author":"S Walther","year":"2010","unstructured":"Walther S, Halpern M. Cannabinoids and dementia: a review of clinical and preclinical data. Pharmaceuticals (Basel). 2010;3(8):2689\u2013708.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"4085_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1021\/mp060066m","volume":"3","author":"LM Eubanks","year":"2006","unstructured":"Eubanks LM, Rogers CJ, Beuscher Iv AE, Koob GF, Olson AJ, Dickerson TJ, et al. A molecular link between the active component of marijuana and Alzheimer\u2019s disease pathology. Mol Pharm. 2006;3(6):773\u20137.","journal-title":"Mol Pharm"},{"key":"4085_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","volume":"172","author":"S Babalonis","year":"2017","unstructured":"Babalonis S, Haney M, Malcolm RJ, Lofwall MR, Votaw VR, Sparenborg S, et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend. 2017;172:9\u201313.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"4085_CR32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.npp.1300340","volume":"29","author":"JA De Souza Crippa","year":"2004","unstructured":"De Souza Crippa JA, Zuardi AW, Garrido GEJ, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of Cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004;29(2):417\u201326.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"4085_CR33","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MHN Chagas","year":"2014","unstructured":"Chagas MHN, Zuardi AW, Tumas V, Pena-Pereira MA, Sobreira ET, Bergamaschi MM, et al. Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28(11):1088\u201392.","journal-title":"J Psychopharmacol"},{"key":"4085_CR34","doi-asserted-by":"publisher","first-page":"874849","DOI":"10.1155\/2015\/874849","volume":"2015","author":"TA Finseth","year":"2015","unstructured":"Finseth TA, Hedeman JL, Brown RP, Johnson KI, Binder MS, Kluger BM. Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson\u2019s disease patients in Colorado. Evid Based Complement Alternat Med. 2015;2015:874849.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"4085_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","volume":"2","author":"K Iffland","year":"2017","unstructured":"Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2(1):139\u201354.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"7460","key":"4085_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/bmj.38149.566979.AE","volume":"329","author":"KB Svendsen","year":"2004","unstructured":"Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329(7460):253.","journal-title":"BMJ"},{"issue":"3","key":"4085_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1089\/can.2018.0020","volume":"4","author":"C Purcell","year":"2019","unstructured":"Purcell C, Davis A, Moolman N, Taylor SM. Reduction of benzodiazepine use in patients prescribed medical cannabis. Cannabis Cannabinoid Res. 2019;4(3):214\u20138.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"4085_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000498924","volume":"2","author":"B Broers","year":"2019","unstructured":"Broers B, Pat\u00e0 Z, Mina A, Wampfler J, de Saussure C, Pautex S. Prescription of a THC\/CBD-based medication to patients with dementia: a pilot study in Geneva. Med Cannabis Cannabinoids. 2019;2(1):56\u20139.","journal-title":"Med Cannabis Cannabinoids"},{"issue":"4","key":"4085_CR39","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","volume":"185","author":"S Walther","year":"2006","unstructured":"Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology. 2006;185(4):524\u20138.","journal-title":"Psychopharmacology"},{"issue":"1","key":"4085_CR40","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/gps.1828","volume":"23","author":"MJ Passmore","year":"2008","unstructured":"Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int J Geriatr Psychiatry. 2008;23(1):116\u20137.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3\u20134","key":"4085_CR41","first-page":"142","volume":"10","author":"S Amanullah","year":"2013","unstructured":"Amanullah S, MacDougall K, Sweeney N, Coffin J, Cole J. Synthetic cannabinoids in dementia with agitation: case studies and literature review. Clin Neuropsychiatry. 2013;10(3\u20134):142\u20137.","journal-title":"Clin Neuropsychiatry"},{"issue":"2","key":"4085_CR42","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/0269881116665357","volume":"31","author":"GAH van den Elsen","year":"2017","unstructured":"van den Elsen GAH, Tobben L, Ahmed AIA, Verkes RJ, Kramers C, Marijnissen RM, et al. Effects of tetrahydrocannabinol on balance and gait in patients with dementia: a randomised controlled crossover trial. J Psychopharmacol. 2017;31(2):184\u201391.","journal-title":"J Psychopharmacol"},{"issue":"23","key":"4085_CR43","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","volume":"84","author":"GAH van den Elsen","year":"2015","unstructured":"van den Elsen GAH, Ahmed AIA, Verkes RJ, Kramers C, Feuth T, Rosenberg PB, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial. Neurology. 2015;84(23):2338\u201346.","journal-title":"Neurology"},{"issue":"3","key":"4085_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1089\/acm.2018.0319","volume":"25","author":"M Sexton","year":"2019","unstructured":"Sexton M, Cuttler C, Mischley LK. A survey of cannabis acute effects and withdrawal symptoms: differential responses across user types and age. J Altern Complement Med. 2019;25(3):326\u201335.","journal-title":"J Altern Complement Med"},{"issue":"3","key":"4085_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"issue":"5 Suppl 6","key":"4085_CR46","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","volume":"48","author":"JL Cummings","year":"1997","unstructured":"Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10\u20136.","journal-title":"Neurology"},{"issue":"6","key":"4085_CR47","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.colegn.2016.11.005","volume":"24","author":"L Brett","year":"2017","unstructured":"Brett L, Traynor V, Stapley P, Meedya S. Acceptability of the Cohen-Mansfield Agitation Inventory in an Australian residential aged care facility. Collegian. 2017;24(6):579\u201384.","journal-title":"Collegian"},{"issue":"3","key":"4085_CR48","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/00006842-200205000-00016","volume":"64","author":"RG Logsdon","year":"2002","unstructured":"Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med. 2002;64(3):510\u20139.","journal-title":"Psychosom Med"},{"issue":"1","key":"4085_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/geront\/45.suppl_1.27","volume":"45","author":"P Edelman","year":"2005","unstructured":"Edelman P, Fulton BR, Kuhn D, Chang CH. A comparison of three methods of measuring dementia-specific quality of life: perspectives of residents, staff, and observers. Gerontologist. 2005;45(1):27\u201336.","journal-title":"Gerontologist"},{"issue":"1","key":"4085_CR50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.12968\/ijpn.2004.10.1.12013","volume":"10","author":"J Abbey","year":"2004","unstructured":"Abbey J, Piller N, Bellis AD, Esterman A, Parker D, Giles L, et al. The Abbey Pain Scale: a 1-minute numerical indicator for people with end-stage dementia. Int J Palliat Nurs. 2004;10(1):6\u201313.","journal-title":"Int J Palliat Nurs"},{"issue":"6","key":"4085_CR51","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/pst.1638","volume":"13","author":"DV Mehrotra","year":"2014","unstructured":"Mehrotra DV. A recommended analysis for 2 \u00d7 2 crossover trials with baseline measurements. Pharm Stat. 2014;13(6):376\u201387.","journal-title":"Pharm Stat"},{"issue":"15","key":"4085_CR52","first-page":"276","volume":"109","author":"S Wellek","year":"2012","unstructured":"Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2012;109(15):276\u201381.","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"4085_CR53","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1111\/jgs.13473","volume":"63","author":"HF Mao","year":"2015","unstructured":"Mao HF, Kuo CA, Huang WN, Cummings JL, Hwang TJ. Values of the minimal clinically important difference for the Neuropsychiatric Inventory questionnaire in individuals with dementia. J Am Geriatr Soc. 2015;63(7):1448\u201352.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"4085_CR54","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/JCP.0b013e31820e861c","volume":"31","author":"S Walther","year":"2011","unstructured":"Walther S, Sch\u00fcpbach B, Seifritz E, Homan P, Strik W. Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol. 2011;31(2):256\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"4085_CR55","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.","edition":"5"},{"issue":"10","key":"4085_CR56","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1017\/S1041610215000435","volume":"27","author":"E Beattie","year":"2015","unstructured":"Beattie E, O\u2019Reilly M, Moyle W, Chenoweth L, Fetherstonhaugh D, Horner B, et al. Multiple perspectives on quality of life for residents with dementia in long term care facilities: protocol for a comprehensive Australian study. Int Psychogeriatr. 2015;27(10):1739\u201347.","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"4085_CR57","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s11136-004-1258-0","volume":"14","author":"TP Ettema","year":"2005","unstructured":"Ettema TP, Dr\u00f6es RM, de Lange J, Mellenbergh GJ, Ribbe MW. A review of quality of life instruments used in dementia. Qual Life Res. 2005;14(3):675\u201386.","journal-title":"Qual Life Res"},{"issue":"2","key":"4085_CR58","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s11136-013-0504-8","volume":"23","author":"J Gr\u00e4ske","year":"2014","unstructured":"Gr\u00e4ske J, Verbeek H, Gellert P, Fischer T, Kuhlmey A, Wolf-Ostermann K. How to measure quality of life in shared-housing arrangements? A comparison of dementia-specific instruments. Qual Life Res. 2014;23(2):549\u201359.","journal-title":"Qual Life Res"},{"issue":"2","key":"4085_CR59","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jpainsymman.2017.09.001","volume":"55","author":"AH Lichtman","year":"2018","unstructured":"Lichtman AH, Lux EA, McQuade R, et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manag. 2018;55(2):179\u201388.e1.","journal-title":"J Pain Symptom Manag"},{"key":"4085_CR60","volume-title":"Clinical guidance: for the use of medicinal cannabis products in Queensland","author":"Queensland Health","year":"2018","unstructured":"Queensland Health. Clinical guidance: for the use of medicinal cannabis products in Queensland. 2018. https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0023\/634163\/med-cannabis-clinical-guide.pdf. Accessed 20 Nov 2018."},{"issue":"4","key":"4085_CR61","first-page":"276","volume":"94","author":"TR Reese","year":"2016","unstructured":"Reese TR, Thiel DJ, Cocker KE. Behavioral disorders in dementia: appropriate nondrug interventions and antipsychotic use. Am Fam Physician. 2016;94(4):276\u201382.","journal-title":"Am Fam Physician"},{"issue":"11","key":"4085_CR62","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1017\/S1041610216000922","volume":"28","author":"A Feast","year":"2016","unstructured":"Feast A, Moniz-Cook E, Stoner C, Charlesworth G, Orrell M. A systematic review of the relationship between behavioral and psychological symptoms (BPSD) and caregiver well-being. Int Psychogeriatr. 2016;28(11):1761\u201374.","journal-title":"Int Psychogeriatr"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4085-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-020-4085-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4085-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T14:39:55Z","timestamp":1613227195000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-4085-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4085"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-4085-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.9970\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9970\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9970\/v3","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"assertion":[{"value":"16 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval has been granted by the Human Research Ethics Committee at the University of Notre Dame Australia (UNDA; approval number 018091F). All participants, including the residents and their family members, will need to consent to participate. The results gathered beyond this protocol paper will be presented for the total sample, not for individual cases, and all participants will be given a unique identification number to de-identify their information.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that there may be a perceived conflict of interest in undertaking research funded by MGC Pharmaceuticals, the manufacturer of the drug used in the trial; a number of precautionary steps have been implemented to minimise these. These steps include input on study design and drug doses obtained in the development of the research protocol and securing TGA approval for provision of the drug. All MGC Pharmaceuticals staff will be excluded from the trial itself, including the data collection as well as analysis and interpretation of the data. In joint management meetings, the progress of the study will only be discussed in broad terms to ensure compliance with budgetary issues and appropriate responses to any serious adverse events. UNDA has written permission from MGC Pharmaceuticals Ltd. for a worldwide, non-exclusive, royalty-free license to use the project intellectual property for non-commercial research purposes, including consent to publish research findings regardless of the results. The results will be disseminated via brief reports provided to the participating aged care facilities, as well as through manuscript publications and conference presentations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}